Is Acrivon Therapeutics, Inc. Common Stock (ACRV) a Buy, Sell, or Hold?
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
$1.91 USD
-$0.22 (-10.33%)
- Volume
- 339.33K
- Average Volume
- 577.41K
- Market Capitalization
- $60.27M
- P/E Ratio
- -0.96
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $3.56
- Year Low
- $1.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.98
| Source | Headline |
|---|---|
|
Acrivon Therapeutics: Priced For Failure, Built For Precision
Acrivon Therapeutics (ACRV) trades below cash value, with the market deeply discounting its platform and pipeline despite promising early data. ACRV's AP3 platform enables precision patient-matching for kinase inhibitor therapies, showing a 50% response rate in serous endometrial cancer with ACR-368. Key near-term catalysts include Phase 2b ACR-368 data and Phase 1 ACR-2316 expansion results, both critical for de-risking and expanding commercial potential. seekingalpha.com - 2026-07-13 04:44:48 |
|
Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit
WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D. globenewswire.com - 2026-05-21 07:30:00 |
|
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of May 15, 2026. globenewswire.com - 2026-05-15 16:00:00 |
|
Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026 globenewswire.com - 2026-05-13 16:10:00 |
|
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition globenewswire.com - 2026-04-17 16:00:00 |
|
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of April 15, 2026. globenewswire.com - 2026-04-15 16:05:00 |
